Outcome for Advanced or Metastatic Soft Tissue Sarcoma of Nonextremities Treated with Doxorubicin-Based Chemotherapy: A Retrospective Study from a Single Cancer Institution

Background. Doxorubicin is the key drug for treatment of advanced soft tissue sarcoma (STS). The appropriate dosage of doxorubicin, regarding monotherapy or the role of combination therapy, is unclear. Methods. We retrospectively reviewed patients with advanced or metastatic STS of nonextremities who were treated with doxorubicin-based chemotherapies in our institution. Time to treatment failure (TTF), overall survival (OS), overall response, and prognostic factors for OS were evaluated. Results. Seventy-five patients were enrolled. The median TTF was 4.7 months, and the median OS was 20.1 months. The overall response rate was 20%. Doses of doxorubicin monotherapy did not show significant difference either in TTF or in OS. There were no significant differences in OS between combination therapy and monotherapy, but the TTF with combination therapy was better than monotherapy. The overall response for combination therapy indicated a better response rate. Less number of involved organs, no bulky mass, and a normal CRP level were independent favorable prognostic factors for OS. Conclusions. Combination therapy showed better response and TTF than monotherapy but did not show better OS. Possible prognostic factors for OS were indicated. This retrospective study was approved by the institutional review board. This trial is registered with UMIN000028787.

Download Full-text

Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients

Journal of Clinical Oncology ◽

10.1200/jco.2004.05.210 ◽

2004 ◽

Vol 22 (5) ◽

pp. 890-899 ◽

Cited By ~ 217

Author(s):

A. Yovine ◽

M. Riofrio ◽

J.Y. Blay ◽

E. Brain ◽

J. Alexandre ◽

...

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Febrile Neutropenia ◽

Disease Progression ◽

Phase Ii ◽

Overall Response Rate ◽

Response Rate ◽

Phase Ii Study ◽

Overall Response ◽

Grade 3

Purpose A multicenter phase II study evaluating efficacy, safety, and pharmacokinetics of ecteinascidin-743 (ET-743) in pretreated advanced soft tissue sarcoma patients. Patients and Methods Patients received ET-743 1,500 μg/m2 (24-hour intravenous infusion) every 3 weeks (group 1, 26 patients with one to two prior single agents or one previous combination chemotherapy; group 2, 28 patients with three or more prior single agents or two or more previous combination chemotherapies). Results Patients (30 women, 24 men) had a median age of 48 years (range, 22 to 71 years); 41% had leiomyosarcoma (eight of 22 of uterine origin), a median of two involved organs (range, one to four), and 93% had documented progressive disease at study entry. Patients received a median of three cycles (range, one to 20); 28% received six or more cycles. Fifty-two patients were assessable for response (WHO criteria): two partial responses, four minor responses, and nine with stable disease (≥ 6 months). Three patients were rendered tumor free after surgery. Median progression-free survival was 1.9 months (range, 0.69 to 17.90 months); 24% of patients were progression free at 6 months. Median survival was 12.8 months, with 30% of patients alive at 2 years. Four patients withdrew because of treatment-related toxicity. Two treatment-related deaths occurred (renal failure and febrile neutropenia, and rhabdomyolysis and decompensated cirrhosis, respectively) that were probably related to protocol eligibility violations. Reversible grade 3 to 4 AST or ALT occurred in 50% of patients and grade 3 to 4 neutropenia occurred in 61% of patients, with six episodes of febrile neutropenia. Nausea, vomiting, and asthenia were prevalent but mild and manageable. Conclusion With a 4% overall response rate (95% CI, 0.5 to 12.8) and an 11% rate of third-party-verified tumor regression (overall response rate + minor response), ET-743 has a 24% 6-month disease progression control rate, confirming evidence of antitumoral activity and a manageable safety profile in patients experiencing disease progression with pretreated soft tissue sarcoma.

Download Full-text

Survival after pulmonary metastasectomy in soft tissue sarcoma: Prognostic factors in 214 patients

Acta Orthopaedica Scandinavica ◽

10.3109/17453679509002316 ◽

1995 ◽

Vol 66 (6) ◽

pp. 561-568 ◽

Cited By ~ 72

Author(s):

Peter F M Choong ◽

Douglas J Pritchard ◽

Michael G Rock ◽

Franklin H Sim ◽

Frank J Frassica

Keyword(s):

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Pulmonary Metastasectomy

Download Full-text

Prognostic Factors and Oncological Outcomes of 122 Head and Neck Soft Tissue Sarcoma Patients Treated at a Single Institution

Annals of Surgical Oncology ◽

10.1245/s10434-014-3870-8 ◽

2014 ◽

Vol 22 (1) ◽

pp. 248-255 ◽

Cited By ~ 20

Author(s):

Jin Taek Park ◽

Jong-Lyel Roh ◽

Seon-Ok Kim ◽

Kyung-Ja Cho ◽

Seung-Ho Choi ◽

...

Keyword(s):

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Head And Neck ◽

Single Institution ◽

Oncological Outcomes

Download Full-text

Multivariate analysis for clinical prognostic factors in 163 patients with soft tissue sarcoma

Cancer ◽

10.1002/1097-0142(19881001)62:7<1444::aid-cncr2820620733>3.0.co;2-l ◽

1988 ◽

Vol 62 (7) ◽

pp. 1444-1450 ◽

Cited By ~ 67

Author(s):

Takafumi Ueda ◽

Katsuyuki Aozasa ◽

Masahiko Tsujimoto ◽

Hideki Hamada ◽

Hideki Hayashi ◽

...

Keyword(s):

Multivariate Analysis ◽

Prognostic Factors ◽

Soft Tissue ◽

Soft Tissue Sarcoma

Download Full-text

Retroperitoneal Soft-Tissue Sarcoma: Retrospective Study from a Cancer Hospital in Pakistan

Journal of Surgery and Research ◽

10.26502/jsr.10020110 ◽

2021 ◽

Vol 04 (01) ◽

Author(s):

Jibran Mohsin ◽

Aun Jamal ◽

Noor-ul Mubeen ◽

Aamir Ali Syed

Keyword(s):

Retrospective Study ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Cancer Hospital ◽

Retroperitoneal Soft Tissue Sarcoma

Download Full-text

Clinicopathological study of soft tissue sarcoma-retrospective study of tertiary cancer institute in eastern India

International Journal of Research in Medical Sciences ◽

10.18203/2320-6012.ijrms20204907 ◽

2020 ◽

Vol 8 (11) ◽

pp. 4075

Author(s):

Kunhi Mohammed K. P. ◽

Snehasis Pradhan ◽

Supratim Bhattacharyya ◽

Prafulla Kumar Das ◽

Muhammed Navas N. K.

Keyword(s):

Retrospective Study ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Malignant Tumors ◽

Soft Tissue Sarcomas ◽

The Body ◽

Female Ratio ◽

Pleomorphic Sarcoma ◽

Frequent Variety ◽

Male To Female

Background: Soft tissue sarcomas are a rare and heterogeneous group of malignant tumors of mesenchymal origin that comprise less than 1 percent of all adult malignancies. Although they occur anywhere in the body, they involve most commonly in extremities, trunk, retroperitoneum and head and neck. The aim of the study was to analyze clinical and histopathological features of various soft tissue sarcomas.Methods: This was a retrospective study, conducted in tertiary cancer centre in Odisha during the period 2015 to 2018. We collected clinical parameters like age, sex, site of swelling, any associated pain and biopsy reports and these variables were correlated with final histopathology reports.Results: A total of 107 patients were included in the study, with male to female ratio of 2:1(71 and 36) and average age of 43.45 years. All of them presented with a swelling. The lower extremities were the most common sites i.e. 44.62%. Pleomorphic sarcoma was the most frequent histologic variety comprising 43% and less frequent variety were angiosarcoma, and myxoid sarcoma.Conclusions: Soft tissue sarcoma are predominant in males and middle aged population are frequently affected. Most common affected site is lower extremity and pleomorphic sarcoma is the prominent histologic type.

Download Full-text

The Effect of Systemic Methotrexate and Cyclosporine Combination Therapy inPsoriasis Vulgaris Patients in Bandung, Indonesia

Berkala Ilmu Kesehatan Kulit dan Kelamin ◽

10.20473/bikk.v33.3.2021.200-204 ◽

2021 ◽

Vol 33 (3) ◽

pp. 200

Author(s):

Oki Suwarsa ◽

Fatima Aulia Khairani ◽

Syawalika Ulya Isneny ◽

Erda Avriyanti ◽

Hartati Purbo Dharmadji ◽

...

Keyword(s):

Retrospective Study ◽

Side Effects ◽

Adverse Effects ◽

Combination Therapy ◽

Combination Treatment ◽

Psoriasis Vulgaris ◽

Severity Index ◽

Dermatology Clinic ◽

Significant Difference ◽

Pasi Score

Background: Methotrexate (MTX) and cyclosporine have been used as effective systemic mono-therapy for psoriasis. Several factors are considered to switch monotherapy to combination therapy because monotherapy is no longer effective and has higher side effects. Hence,clinicians have avoided systemic therapy combinations due to its toxicity. However, some studies showed that this combination therapy could be usedeffectively for psoriasis patients. Purpose: This study aimed to analyze the efficacy and adverse effects of systemic MTX and cyclosporine combination therapy in Indonesian psoriasis vulgaris patients. Methods: The retrospective study assessed the effectiveness of 3 monthsmono-therapyand combination therapy of systemic MTX and cyclosporine in psoriasisvulgaris patients from 2016–2017 in Dermatology Clinic, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia. Result: Psoriasis area and severity index (PASI) score 90 were achieved in the group MTX (50%) and cyclosporine group (50%), while none in the combination group.However, eight patients (50%) in group MTX and cyclosporine reached the primary endpoint of PASI 50. One patient in cyclosporine group had adverse effects on kidney profiles. Nonetheless, other patients had no biochemical changes. But, there was no significant difference in the change of PASI between each group (p=0.102). Conclusion: We propose that combination therapy of MTX and cyclosporine is relatively safe and efficacious in treating Indonesian psoriasis vulgaris patients. This combination treatment isas effective as MTX or cyclosporinemono-therapy.

Download Full-text

Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: a retrospective study of 679 adult cases

Rheumatology ◽

10.1093/rheumatology/keaa372 ◽

2020 ◽

Author(s):

Shan Li ◽

Yuxin Sun ◽

Chi Shao ◽

Hui Huang ◽

Qian Wang ◽

...

Keyword(s):

Prognostic Factors ◽

Retrospective Study ◽

Interstitial Lung Disease ◽

Lung Disease ◽

Inflammatory Myopathy ◽

Idiopathic Inflammatory Myopathy ◽

Mortality Rates ◽

Trna Synthetase ◽

Significant Difference ◽

All Cause Mortality

Abstract Objectives Few studies have investigated the prognostic factors for idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) across different clinical/serological phenotypes. Methods We conducted a retrospective analysis of patients diagnosed with IIM between January 2012 and December 2017. Results Of the 760 IIM cases registered, 679 adult cases were included in this study. ILD was present in 508 cases, and the presence of ILD in the clinically amyopathic DM, DM and PM groups was 92.7, 73.6 and 55.1%, respectively (P < 0.01). The prevalence of ILD in the anti-synthetase antibody (ASA)+-IIM group was higher than that in ASA–-IIM group (95.2 vs 72.4%, P < 0.01); no such difference was found between the anti-histidyl-tRNA synthetase (Jo-1)+-IIM and Jo-1–ASA+-IIM groups (93.0 vs 98.5%, P > 0.05). The prevalence of ILD in the melanoma differentiation-associated protein-5 (MDA-5)+-IIM group was higher than that in MDA-5–-IIM group (97.8 vs 72.1%, P < 0.01). Among adults with IIM, men with concurrent ILD, who were older than 50 years, were most likely to die. No significant difference was found in the all-cause mortality rates between DM-ILD and clinically amyopathic DM-ILD groups (33.3 vs 23%, P > 0.05), although both were higher than that in PM group (13.2%, P = 0.01 and P < 0.05, respectively). No difference was found in the all-cause mortality rates between MDA5–ASA–-IM-ILD and MDA5–ASA+-IM-ILD groups (17.2 vs 12.8%, P > 0.05), and both were lower than that in MDA5+ASA–-IM-ILD group (33.7%, P < 0.05). Conclusion The prevalence of ILD in IIM and the prognosis of IIM-ILD patients may vary depending on the statuses of the ASA and MDA-5 antibodies.

Download Full-text